Drugs in the Pipeline
Dupilumab Under Review for Pediatric Asthma
The submission was based on data from the double-blind, placebo-controlled VOYAGE trial.
Your search for oral corticosteroids returned 8 results
News
Dupixent Prefilled Pen Approval Provides Additional Administration Option
The FDA has approved a prefilled pen formulation of Dupixent (dupilumab; Sanofi and Regeneron), providing another option for administering the treatment.
News
ACAAI: Statement on Corticosteroid Use for Allergies, Asthma During COVID-19 Pandemic
The American College of Allergy, Asthma and Immunology (ACAAI) has issued a statement regarding the use of corticosteroids for patients with allergies and asthma.
Drugs in the Pipeline
Oral Tyrosine Kinase Inhibitor Effective in Severe Asthma Trial
Treatment with masitinib, a selective tyrosine kinase inhibitor, significantly reduces the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids, according to data from a phase 3 study.
News
Rituximab Compared With Mycophenolate Mofetil in Pemphigus Vulgaris Trial
Rituximab was found to be superior to mycophenolate mofetil (MMF) in adult patients with severe pemphigus vulgaris, according to new phase 3 trial data.
News
Real-World Study Shows Mepolizumab Reduces Exacerbations in Patients With Severe Eosinophilic Asthma
Treatment with mepolizumab was associated with a significant reduction in asthma exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma.
News
Exploratory Data Show Additional Benefits of Vedolizumab in Ulcerative Colitis
New exploratory data published in the New England Journal of Medicine further provide evidence of the benefits of vedolizumab (Entyvio; Takeda), an integrin receptor antagonist, when compared with adalimumab (Humira; AbbVie), a tumor necrosis factor-alpha (TNFα) antagonist, in patients with moderately to severely active ulcerative colitis. In the phase 3b VARSITY study, patients were randomized…
News
Dupixent Approved for Chronic Rhinosinusitis With Nasal Polyps
The Food and Drug Administration (FDA) has approved Dupixent (dupilumab; Sanofi and Regeneron) as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP). The approval was based on data from two phase 3 randomized, double blind, placebo controlled trials (SINUS-24 and SINUS-52) that evaluated the safety and efficacy…
